TIDMGDR

Genedrive PLC

03 December 2020

genedrive plc

("genedrive" or the "Company")

Antibiotic Induced Hearing Loss assay hospital trial completion

Genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces the successful completion of the Antibiotic Induced Hearing Loss ("AIHL") implementation study into the use of the genetic test in an NHS neonatal intensive care setting.

The Genedrive(R) MT-RNR1 ID Kit has been used over the past 11 months in a trial of what is thought to be a world first use of a genetic test in a neonatal intensive care setting. The Genedrive assay has been used at Manchester University NHS Foundation Trust and Liverpool Women's Hospital to screen babies before administering certain antibiotics that are known to cause deafness in infants.

Over the period of the study, approximately 750 babies have been tested with the Genedrive MT-RNR1 Kit, with all valid results being confirmed by DNA sequencing. Genedrive is now working with the study team to publish the data, due in early 2021, and with Inspiration Healthcare plc to plan the roll-out for commercial use. Full launch of the product is expected from June 2021, following the inclusion of feedback from the trial sites in the product configuration.

David Budd, CEO of genedrive plc, said: "The completion of the AIHL study is an important milestone in the development and commercialisation of our novel test. We have developed a unique assay with compelling health economic benefits which can provide a clinically actionable result in a relevant timeframe, and ultimately could positively alter the lives of thousands of babies every year."

For further details please contact:

 
 genedrive plc                                                                 +44 (0)161 989 0245 
 David Budd: CEO / Matthew Fowler: 
  CFO 
 
 Peel Hunt LLP (Nominated Adviser 
  and Joint Broker)                                                            +44 (0)20 7418 8900 
 James Steel / Oliver Jackson 
 
            finnCap (Joint Broker)                                             +44 (0)20 7220 0500 
            Geoff Nash / Kate Bannatyne / Alice 
             Lane 
 
 Walbrook PR Ltd (Media & Investor                 +44 (0)20 7933 8780 or genedrive@walbrookpr.com 
  Relations) 
                                                                 +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                                741 001

About genedrive plc ( http://www.genedriveplc.com )

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive(R) Point of Care version of the assay, both based on Genedrive(R) chemistry.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFSDFMEESSEFE

(END) Dow Jones Newswires

December 03, 2020 02:00 ET (07:00 GMT)

Epistem (LSE:EHP)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Epistem Charts.
Epistem (LSE:EHP)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Epistem Charts.